For instance, TFAP2A potentiates lung adenocarcinoma metastasis and stimulates angiogenesis in lung cancer cells with acquired resistance to anlotinib [37, 38]; TFAP2A-mediated activation of E2F and EZH2 drives melanoma metastasis [39]. Here, EZH2 is linked to lung adenocarcinoma.